FONAR Corporation
NASDAQ:FONRMedical - Devices
+$0.00 today
- Market cap
- $117.76M
- Beta
- 0.95
- P/E (TTM)
- 17.6
- EPS (TTM)
- $1.08
Volume 0.00M
Average 0.08M
FONR EBITDA Margin
EBITDA as a percentage of revenue.
FONAR CorporationNASDAQ: FONR
EBITDA Margin · Q3 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 14.8%
EBITDA Margin was 14.8% in Q3 FY2026, down 4.9 pp from a year earlier. On a trailing-twelve-month basis it was 15.1%, down 3.2 pp year over year. Over 3 fiscal years it narrowed by 10.6 pp.
Context
- EBITDA Margin widened in 0 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 17.7%
- Year-over-year change
- -5.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 17.7% | -5.5pp |
| FY2024 | 2024-06-30 | 23.3% | -1.7pp |
| FY2023 | 2023-06-30 | 25.0% | -3.4pp |
| FY2022 | 2022-06-30 | 28.3% | +3.9pp |
| FY2021 | 2021-06-30 | 24.5% | — |
EBITDA Margin vs competitors
How FONR compares with its peers on the latest reported figures
- FONR's LTM Mar 2026 EBITDA Margin of 15.1% is the highest of the 6 companies compared; the peer median is -54.5%.
- Its year-over-year change of -3.2 pp is the 5th highest of 6, against a peer median of +18.1 pp.
- Over three fiscal years its change of -10.6 pp compares with a peer median of +45.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 15.1% | -3.2 pp | -10.6 pp | |
| LTM Mar 2026 | -4.4% | +24.0 pp | +40.8 pp | |
| LTM Mar 2026 | -52.1% | +18.1 pp | +20.4 pp | |
| LTM Mar 2026 | -54.5% | +6.4 pp | +50.0 pp | |
| LTM Mar 2026 | -216.2% | +118.9 pp | +812.8 pp | |
| LTM Mar 2026 | -144435.8% | -111246.8 pp | — | |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding FONR) | -54.5% | +18.1 pp | +45.4 pp | |
Competitors are the stored peer set for FONR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 89.93M | 97.59M | 98.65M | 102.88M | 104.35M |
| Cost of Revenue | 46.46M | 50.58M | 52.9M | 57.74M | 61.44M |
| Gross Profit | 43.47M | 47.01M | 45.75M | 45.14M | 42.91M |
| Gross Margin | 48.3% | 48.2% | 46.4% | 43.9% | 41.1% |
| Research & Development | 1.64M | 1.49M | 1.57M | 1.74M | 1.58M |
| Selling, General & Admin | 0 | 0 | 29.39M | 0 | 29.73M |
| Operating Expenses | 26.38M | 25.01M | 30.96M | 28.6M | 31.31M |
| Depreciation & Amortization | 4.08M | 4.54M | 8.8M | 4.6M | 4.7M |
| EBITDA | 22M | 27.65M | 24.61M | 23.94M | 18.5M |
| EBITDA Margin | 24.5% | 28.3% | 25.0% | 23.3% | 17.7% |
| Operating Income | 17.1M | 22.01M | 14.79M | 16.54M | 11.6M |
| Operating Margin | 19.0% | 22.6% | 15.0% | 16.1% | 11.1% |
| Interest Income | 0 | 0 | 0 | 0 | 2.17M |
| Interest Expense | 248.67K | 346.55K | 50.13K | 77K | 25.61K |
| Other Income / Expenses | 567.72K | 761.69K | 969.33K | 2.73M | 2.18M |
| Income Before Tax | 17.67M | 22.77M | 15.76M | 19.27M | 13.78M |
| Pre-Tax Margin | 19.6% | 23.3% | 16.0% | 18.7% | 13.2% |
| Income Tax Expense | 3.99M | 5.53M | 3.63M | 5.17M | 3.11M |
| Net Income | 10.21M | 12.44M | 9.38M | 10.57M | 8.33M |
| Net Margin | 11.4% | 12.7% | 9.5% | 10.3% | 8.0% |
| EPS (Basic) | 1.47 | 1.78 | 1.35 | 1.56 | 1.26 |
| EPS (Diluted) | 1.45 | 1.75 | 1.32 | 1.53 | 1.23 |
| Weighted Avg Shares | 6.61M | 6.55M | 6.65M | 6.35M | 6.32M |
| Weighted Avg Shares (Diluted) | 6.74M | 6.68M | 6.77M | 6.48M | 6.55M |
FONAR Corporation
NASDAQ:FONR
Intrinsic Alpha fair value
Locked
Current Price
$19.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.